Anna M. Schläfli

859 total citations
17 papers, 668 citations indexed

About

Anna M. Schläfli is a scholar working on Molecular Biology, Epidemiology and Hematology. According to data from OpenAlex, Anna M. Schläfli has authored 17 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Epidemiology and 5 papers in Hematology. Recurrent topics in Anna M. Schläfli's work include Autophagy in Disease and Therapy (14 papers), RNA modifications and cancer (6 papers) and Acute Myeloid Leukemia Research (5 papers). Anna M. Schläfli is often cited by papers focused on Autophagy in Disease and Therapy (14 papers), RNA modifications and cancer (6 papers) and Acute Myeloid Leukemia Research (5 papers). Anna M. Schläfli collaborates with scholars based in Switzerland, United States and Italy. Anna M. Schläfli's co-authors include Mario P. Tschan, Rupert Langer, Sabina Berezowska, Olivia Adams, Enrico Garattini, Ralph A. Schmid, Magali Humbert, Bruce E. Torbett, Daniel Brigger and Bastian Dislich and has published in prestigious journals such as Scientific Reports, Biochemical and Biophysical Research Communications and International Journal of Molecular Sciences.

In The Last Decade

Anna M. Schläfli

17 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna M. Schläfli Switzerland	13	433	370	128	90	77	17	668
Can Tan United States	9	492 1.1×	122 0.3×	70 0.5×	104 1.2×	102 1.3×	22	715
Michelle Cicchini United States	9	412 1.0×	223 0.6×	160 1.3×	69 0.8×	188 2.4×	9	727
Niklas Berleth Germany	12	393 0.9×	246 0.7×	159 1.2×	70 0.8×	41 0.5×	13	619
Nathiya Muthalagu United Kingdom	5	564 1.3×	102 0.3×	168 1.3×	71 0.8×	161 2.1×	8	693
Siao Muk Cheng Taiwan	12	415 1.0×	125 0.3×	110 0.9×	39 0.4×	136 1.8×	26	598
Chen Zong China	16	291 0.7×	207 0.6×	149 1.2×	48 0.5×	125 1.6×	22	689
Rodolfo Chavez-Dominguez Mexico	6	288 0.7×	159 0.4×	142 1.1×	39 0.4×	119 1.5×	12	562
Hala Elnakat Thomas United States	9	312 0.7×	145 0.4×	110 0.9×	45 0.5×	68 0.9×	9	460
Sun Mi Hong South Korea	13	391 0.9×	129 0.3×	139 1.1×	38 0.4×	115 1.5×	21	619
James R. Knabb United States	5	414 1.0×	234 0.6×	227 1.8×	47 0.5×	156 2.0×	5	656

Countries citing papers authored by Anna M. Schläfli

Since Specialization

Citations

This map shows the geographic impact of Anna M. Schläfli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna M. Schläfli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna M. Schläfli more than expected).

Fields of papers citing papers by Anna M. Schläfli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna M. Schläfli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna M. Schläfli. The network helps show where Anna M. Schläfli may publish in the future.

Co-authorship network of co-authors of Anna M. Schläfli

This figure shows the co-authorship network connecting the top 25 collaborators of Anna M. Schläfli. A scholar is included among the top collaborators of Anna M. Schläfli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna M. Schläfli. Anna M. Schläfli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Humbert, Magali, Petra Minder, Anna M. Schläfli, et al.. (2022). Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions. Cell Death and Disease. 13(5). 448–448. 34 indexed citations

Schläfli, Anna M., et al.. (2021). The Multifaceted Functions of Autophagy in Breast Cancer Development and Treatment. Cells. 10(6). 1447–1447. 50 indexed citations

Schläfli, Anna M., Marta Pinto, Magali Humbert, et al.. (2021). Increased LAMP2A levels correlate with a shorter disease-free survival of HER2 negative breast cancer patients and increased breast cancer cell viability. Biochemical and Biophysical Research Communications. 569. 47–53. 7 indexed citations

Schläfli, Anna M., et al.. (2021). ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells. Scientific Reports. 11(1). 9011–9011. 11 indexed citations

Humbert, Magali, Anna M. Schläfli, Christina Neppl, et al.. (2020). Chaperone-Mediated Autophagy Markers LAMP2A and HSC70 Are Independent Adverse Prognostic Markers in Primary Resected Squamous Cell Carcinomas of the Lung. Oxidative Medicine and Cellular Longevity. 2020. 1–12. 22 indexed citations

Jakob, Manuel O., Adrian Keogh, Laure C. Bouchez, et al.. (2019). Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell Death and Disease. 10(10). 749–749. 55 indexed citations

Tschan, Mario P., et al.. (2019). Assessing Autophagy During Retinoid Treatment of Breast Cancer Cells. Methods in molecular biology. 2019. 237–256. 10 indexed citations

Jin, Jing, Adrian Britschgi, Anna M. Schläfli, et al.. (2018). Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy. Oxidative Medicine and Cellular Longevity. 2018(1). 1482795–1482795. 48 indexed citations

Adams, Olivia, Anna M. Schläfli, Bastian Dislich, et al.. (2018). Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells. International Journal of Molecular Sciences. 19(10). 3069–3069. 28 indexed citations

10.

Schläfli, Anna M., Pauline Isakson, Enrico Garattini, Anne Simonsen, & Mario P. Tschan. (2017). The autophagy scaffold protein ALFY is critical for the granulocytic differentiation of AML cells. Scientific Reports. 7(1). 12980–12980. 17 indexed citations

11.

Schläfli, Anna M., Olivia Adams, José A. Galván, et al.. (2016). Prognostic value of the autophagy markers LC3 and p62/SQSTM1 in early-stage non-small cell lung cancer. Oncotarget. 7(26). 39544–39555. 103 indexed citations

12.

Adams, Olivia, Bastian Dislich, Sabina Berezowska, et al.. (2016). Prognostic relevance of autophagy markers LC3B and p62 in esophageal adenocarcinomas. Oncotarget. 7(26). 39241–39255. 45 indexed citations

13.

Brigger, Daniel, Anna M. Schläfli, Enrico Garattini, & Mario P. Tschan. (2015). Activation of RARα induces autophagy in SKBR3 breast cancer cells and depletion of key autophagy genes enhances ATRA toxicity. Cell Death and Disease. 6(8). e1861–e1861. 27 indexed citations

14.

Schläfli, Anna M., Sabina Berezowska, Olivia Adams, Rupert Langer, & Mario P. Tschan. (2015). Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry. European Journal of Histochemistry. 59(2). 2481–2481. 127 indexed citations

15.

Bensadoun, Paul, Élodie Richard, Anna M. Schläfli, et al.. (2014). p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells. Cell Death and Differentiation. 21(12). 1852–1861. 55 indexed citations

16.

Humbert, Magali, Elena Federzoni, Adrian Britschgi, et al.. (2013). The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APL. Journal of Leukocyte Biology. 95(1). 83–93. 22 indexed citations

17.

Schläfli, Anna M., Bruce E. Torbett, Martin F. Fey, & Mario P. Tschan. (2012). BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation. Experimental Hematology and Oncology. 1(1). 25–25. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact